MSN and breast carcinoma: Through a high‐throughput assay based on HER2/ERM interaction to find moesin‐mimicking compounds, we previously identified zuclopenthixol that behaved as moesin in maintaining HER2 in a catalytically repressed state, hence providing a novel therapeutic approach targeting HER2+ breast cancers and brain metastasis [14].